

## 4DMEDICAL LISTS ON THE ASX

---

- 4DMedical lists on the ASX after raising \$55.79 million, with an indicative market capitalisation of \$193 million at \$0.73 per share
  - 4DMedical's XV Technology<sup>™</sup> converts sequences of X-ray images into four-dimensional quantitative data, allowing physicians to better diagnose and treat patients with respiratory diseases
  - FDA 510(k) clearance received for its first Software as a Service (SaaS) offering – XV LVAS
  - XV Technology<sup>™</sup> delivers significant advantages over existing procedures including ability to diagnose earlier and with more sensitivity while using existing hospital and clinic equipment
  - Focused on penetrating the US\$13.7 billion U.S. respiratory diagnostics market
  - Adoption by renowned US medical institutions including Cleveland Clinic & Cedars-Sinai Medical Center
  - Highly defendable IP portfolio covering various jurisdictions
  - The IPO was heavily oversubscribed with support from institutional and retail investors including new and existing shareholders
  - IPO was underwritten by Bell Potter and E&P Corporate Advisory as Joint Lead Managers
- 

**7 August 2020:** 4DMedical Limited (ASX:4DX, "4DMedical" or the "Company"), a medical technology Company focused on commercialising its patented respiratory imaging platform, is pleased to announce it has been admitted to the official list of the Australian Securities Exchange (ASX) following the successful completion of a \$55.79 million initial public offering (IPO).

Under the IPO, the Company issued 76.43 million new shares at \$0.73 per share, which gives 4DMedical a market capitalisation of approximately \$193 million at the IPO price.

Supported by more than 15 years of development, 4DMedical's XV Technology<sup>™</sup> improves the capacity of physicians to diagnose and treat patients with respiratory diseases more efficiently, by providing objective measurements of regional lung motion and air flow. It uses mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data.

In May 2020, the Company received FDA 510(k) clearance for its XV Lung Ventilation Analysis Software (XV LVAS), which is based on the XV Technology<sup>™</sup> platform. XV LVAS is now being sold in the U.S under a Software as a Service (SaaS) business model using existing hospital X-ray equipment, and will be the core driver of near-term sales growth for the Company.

The US\$31 billion global respiratory diagnostic market is dominated by three procedures, the pulmonary function test, the X-ray and the CT. 4D Medical's XV Technology<sup>™</sup> provides compelling advantages that can aid market adoption:

- Provides a non-invasive modality for physicians to understand regional lung motion and air flow, and to identify respiratory deficiencies earlier and more sensitively;
- Designed to be fully compatible with existing hospital and clinic equipment, therefore not requiring any capital expenditure; and
- Will be delivered through a cloud-based Software as a Services (SaaS) model, allowing 4DMedical to deliver its technology more quickly and at a lower cost base to existing procedures.

All of 4DMedical's technology and intellectual property has been pioneered by the Company's in-house development team and validated by a number of clinical trials in partnership with leading U.S. hospitals. The

Company's technology has also been the subject of more than 70 peer-reviewed journal publications and book chapters.

The market for respiratory diagnostics in the U.S., 4DMedical's priority market, is US\$13.7 billion with 73.5 million diagnostic procedures conducted per year. Customers to date include highly regarded medical institutions such as Cedars-Sinai Medical Center and The Cleveland Clinic.

The Company's IP portfolio comprises a total of 43 patents/patent applications, with 15 granted patents and 28 pending patent applications across the U.S., Australia, the European Union and Asia.

Future growth will be driven by the sale of other 4DMedical products as development progresses and necessary regulatory approvals are received. The Company's product pipeline comprises three software solutions and two hardware solutions.

The IPO of 4DMedical was heavily oversubscribed with support from a wide range of institutional and retail investors, including both new and existing shareholders. Funds raised in the IPO will be used to execute the Company's growth strategy, which is predominantly focused on increasing sales and marketing capabilities in the US, its clinical trial strategy to drive market penetration, and investment of additional resources into research and development of its product portfolio.

Bell Potter Securities and E&P Corporate Advisory acted as Joint Lead Managers to the IPO.

**Andreas Fouras, Founder & CEO of 4DMedical said:**

"We have been delighted with the high level of support and interest we have received throughout this process and welcome this significant milestone of becoming a listed company after 15 years of hard work. 4DMedical is focused on its mission to improve global health by providing unique and non-invasive imaging technologies that enable unprecedented insight into pulmonary function.

"Continued growth of the business is a priority, and we are eager to reward our supportive shareholders by delivering long-term value creation."

**ENDS**

Authorised on behalf of the 4DMedical Board of Directors by Andreas Fouras, CEO.

**Contacts:**

<i>Corporate</i>	<i>Investor</i>	<i>Media</i>
Charlene Stahr	Simon Hinsley	Matthew Wright
Company Secretary	+ 61 401 809 653	+ 61 451 896 420
companysecretary@4dmedical.com	shinsley@4dmedical.com	matt@nwrcommunications.com.au

**About 4DMedical:**

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical (formerly 4Dx) was founded in 2013 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a \$30 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.